Original articlesGastrointestinal tumorsNintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
Gastrointestinal tumors
Under a Creative Commons license
open access
Key words
chemorefractory metastatic colorectal cancer
angiogenesis inhibition
nintedanib
Cited by (0)
Note: This study was previously presented as Van Cutsem E, et al. Annals of Oncology 27, 2016 (Suppl 3; abstract LBA20_PR), https://doi.org/10.1093/annonc/mdw435.12
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd.